Array-based DNA methylation profiling of primary lymphomas of the central nervous system

[1]  R. Siebert,et al.  Hunting for the 5th base: Techniques for analyzing DNA methylation. , 2009, Biochimica et biophysica acta.

[2]  R. Siebert,et al.  Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma , 2009, Leukemia.

[3]  R. Spang,et al.  New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. , 2009, Blood.

[4]  P. Meltzer,et al.  Large-scale profiling of archival lymph nodes reveals pervasive remodeling of the follicular lymphoma methylome. , 2009, Cancer research.

[5]  Jian-Bing Fan,et al.  GoldenGate assay for DNA methylation profiling. , 2009, Methods in molecular biology.

[6]  R. Siebert,et al.  Primary lymphoma of the central nervous system: just DLBCL or not? , 2009, Blood.

[7]  M. Esteller,et al.  Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer , 2008, Epigenetics.

[8]  Rajagopalan Srinivasan,et al.  Principal components analysis based methodology to identify differentially expressed genes in time-course microarray data , 2008, BMC Bioinformatics.

[9]  N. Normanno,et al.  The role of the EGFR signaling in tumor microenvironment , 2008, Journal of cellular physiology.

[10]  T. Wolfsberg,et al.  DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status , 2008, Leukemia.

[11]  R. Spang,et al.  Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell , 2008, Leukemia.

[12]  Cheng-Long Huang,et al.  Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. , 2007, Lung cancer.

[13]  Robert Brown,et al.  Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis , 2007, Clinical Cancer Research.

[14]  M. Esteller.  Epigenetic gene silencing in cancer: the DNA hypermethylome. , 2007, Human molecular genetics.

[15]  Anne H. O'Donnell,et al.  Hyperconserved CpG domains underlie Polycomb-binding sites , 2007, Proceedings of the National Academy of Sciences.

[16]  Michael B. Stadler,et al.  Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome , 2007, Nature Genetics.

[17]  D. Louis,et al.  Downregulation of RUNX3 and TES by hypermethylation in glioblastoma , 2007, Oncogene.

[18]  Kelly M. McGarvey,et al.  A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.

[19]  J. Herman,et al.  Epigenetic silencing of multiple genes in primary CNS lymphoma , 2006, International journal of cancer.

[20]  Mitsutoshi Nakamura,et al.  Defective Expression of HRK is Associated with Promoter Methylation in Primary Central Nervous System Lymphomas , 2006, Oncology.

[21]  P. Mires.  Lines , 2006 .

[22]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[23]  司履生.  Cancer epigenetics , 2006 .

[24]  Kristian Helin,et al.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. , 2006, Genes & development.

[25]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.

[26]  Wei Jiang,et al.  High-throughput DNA methylation profiling using universal bead arrays. , 2006, Genome research.

[27]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[28]  D. Schübeler,et al.  Defining epigenetic states through chromatin and RNA , 2005, Nature Genetics.

[29]  J. O'Brien,et al.  Pathology and genetics of primary central nervous system and intraocular lymphoma. , 2005, Hematology/oncology clinics of North America.

[30]  T. Kuroiwa,et al.  Primary malignant lymphoma of the brain: Frequent abnormalities and inactivation of p14 tumor suppressor gene , 2005, Cancer science.

[31]  P. Laird.  Cancer epigenetics. , 2005, Human molecular genetics.

[32]  Andrew P Feinberg,et al.  The epigenetics of cancer etiology. , 2004, Seminars in cancer biology.

[33]  M. Reni,et al.  Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas , 2004, British journal of haematology.

[34]  S. Nomoto,et al.  Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing , 2004, Cancer Research.

[35]  M. Alonso,et al.  CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients. , 2003, Cancer genetics and cytogenetics.

[36]  Leif E. Peterson.  Partitioning large-sample microarray-based gene expression profiles using principal components analysis , 2003, Comput. Methods Programs Biomed..

[37]  P. Laird,et al.  Adenocarcinoma Epigenetic Patterns in the Progression of Esophageal Updated Version , 2001 .

[38]  G. Reifenberger,et al.  Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. , 1999, The American journal of pathology.

[39]  M. Wolter,et al.  Frequent In activation of CDKN2A and Rare Mutation of TP53 in PCNSL , 1998, Brain pathology.

[40]  M. Yuille,et al.  Deletions and rearrangement of CDKN2 in lymphoid malignancy. , 1995, Blood.

[41]  A. Bird,et al.  High levels of De Novo methylation and altered chromatin structure at CpG islands in cell lines , 1990, Cell.